Prostate Cancer

Rahul Aggarwal, MD, discussed the high unmet needs of neuroendocrine prostate cancer, highlighting biopsy triggers, genomic markers, and emerging targets.

The phase 3 TALAPRO-3 study met its primary end point, showing a clinically meaningful reduction in the risk of progression or death in HRR-mutant HSPC.

Benjamin Garmezy, MD, discussed the potential of a GSPT1 molecular glue degrader and a trispecific T-cell engager in treating select prostate cancers.

For patients with more aggressive disease, the addition of chemotherapy to the ARPI/ADT backbone may optimize efficacy outcomes without comprising safety.

Emergent phase 1 LuPARP study data suggest that metastatic castration-resistant prostate cancer could be treated with PARP inhibition and radionuclides.

Twenty patients with low- to intermediate-risk localized prostate cancer underwent successful implantation with the antiandrogen-eluting implants.

By harnessing investigator-generated data, companion diagnostics, and biomarker-directed treatment selection, clinicians can optimize care for HSPC.

Bridget Koontz, MD, discussed evaluating the role of concurrent hormone therapy and brachytherapy for prostate cancer that she presented at ASCO GU.

Oncologists discussed key abstracts assessing AI models for treatment selection, AKT inhibition, and PARP inhibition in specific prostate cancer types.

The triplet regimen also improved health-related quality of life and pain compared with ADT plus ARPI alone in patients with metastatic hormone-sensitive prostate cancer.

Data from PEACE-2 may challenge the current definition of "very high-risk" localized prostate cancer without nodal disease involvement.

Results from the PEACE-3 trial found an extended OS after patients with metastatic castration-resistant prostate cancer were treated with enzalutamide/radium-223.

Data from the CAPItello-281 trial may support capivasertib/abiraterone as a first-in-class targeted therapy in this metastatic hormone-sensitive prostate cancer population.

Data from the phase 2 BRCAAway trial showed the longest survival with olaparib plus abiraterone/prednisone vs each agent given alone or sequentially.

Discover how PSMA PET sharpens staging, guides radioligand therapy sequencing, and tackles real‑world access hurdles in advanced prostate cancer.

Those with intellectual disabilities were less likely to undergo expedient prostate biopsy following an elevated PSA result.

Investigators of the phase 2b trial will enroll approximately 40 men with advanced prostate cancer to undergo treatment with teverelix.

The differences in treatment setting are associational and are likely influenced by confounding by indication and not treatment effects.

A 5-year OS rate of 97.1% was observed among patients who received PSMA PET/CT restaging at first biochemical recurrence following prostatectomy.

Based on the prevalence of GLP-1 agonists employed in standard medical practice, Li’s team will assess their impact on radiotherapy for prostate cancer.

Real-world data presented at the 36th Annual IPCU build upon findings from the phase 3 TITAN trial evaluating apalutamide in this CSPC population.

PSMA-PET could be considered in selective cases, given its modest sensitivity and prognostic value in intermediate-risk prostate cancers.

Phase 2 PFLT-PC data revealed no significant disease was seen in 84% of patients treated with cooled laser focal therapy for prostate cancer at 3 months.

According to investigators, the lack of anti-tumor activity and immunogenicity results do not support the agent’s further development in metastatic CRPC.

Ash Tewari, MBBS, hopes that with institutional partner aid, in 10 years, 1 million men will undergo prostate cancer screening through mobile units.